logo

For the Inventor, By the Inventor

Cambridge, MA, United States of America

Tallessyn Grenfell-Lee

This inventor holds 3 USPTO granted patents and 1 published patent application. Top assignees: Millennium Pharmaceuticals Limited, Mayo Foundation for Medical Education and Research, The University of Texas System. Active years: 2008-2011.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Tallessyn Grenfell-Lee. Retrieved from https://idiyas.com/inventor/tallessyn-grenfell-lee

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 3 

Average Co-Inventor Count = 6.2

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:

goldMedal3 out of 854 
 
Millennium Pharmaceuticals Limited
 patents
silverMedal2 out of 1,809 
 
Mayo Foundation for Medical Education and Research
 patents
bronzeMedal2 out of 5,638 
 
The University of Texas System
 patents
where one patent can have more than one assignee

Years Active: 2008-2011

Loading Chart...
3 patents (USPTO):Explore Patents
1. 8080368 - Compositions and methods for the identification, assessment, prevention and therapy of human cancers (2011-12-20),
2. 7871775 - Compositions and methods for the identification, assessment, prevention and therapy of human cancers (2011-01-18),
3. 7338758 - Compositions and methods for the identification, assessment, prevention and therapy of human cancers (2008-03-04),

Title: The Innovative Contributions of Tallessyn Grenfell-Lee

Introduction

Tallessyn Grenfell-Lee is a notable inventor based in Cambridge, MA (US). He has made significant contributions to the field of cancer research, holding a total of 3 patents. His work focuses on the identification and assessment of therapeutic targets for human cancers.

Latest Patents

One of his latest patents is centered on compositions and methods for the identification, assessment, prevention, and therapy of human cancers. This invention is directed towards identifying markers that can determine whether tumors are sensitive or resistant to therapeutic agents. It features a variety of 'sensitivity markers' that are expressed in cell lines sensitive to treatment, as well as 'resistance markers' found in resistant cell lines. Additionally, the invention includes marker sets that can predict patient responses to specific agents.

Career Highlights

Tallessyn has worked with prominent organizations such as Millennium Pharmaceuticals Limited and the University of Texas System. His experience in these institutions has allowed him to advance his research and contribute to the development of innovative cancer therapies.

Collaborations

He has collaborated with esteemed colleagues, including Lynn C Hartmann and Karen Lu, further enhancing the impact of his research in the scientific community.

Conclusion

Tallessyn Grenfell-Lee's work exemplifies the vital role of innovation in cancer research. His patents and collaborations reflect a commitment to improving therapeutic strategies for patients.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…